FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034000571> ?p ?o ?g. }

• W2034000571 endingPage "757" @default.
• W2034000571 startingPage "749" @default.
• W2034000571 abstract "Background: Integrins mediate invasion and angiogenesis in prostate cancer bone metastases. We conducted a phase II study of Cilengitide, a selective antagonist of αvβ3 and αvβ5 integrins, in non-metastatic castration resistant prostate cancer with rising PSA. Methods: Patients were observed for 4 weeks with PSA monitoring, and then treated with 2,000 mg IV of cilengitide twice weekly until toxicity/progression. PSA, circulating tumor cells (CTCs) and circulating endothelial cells (CECs) were monitored each cycle with imaging performed every three cycles. Primary end point was PSA decline by ≥50%. Secondary endpoints were safety, PSA slope, time to progression (TTP), overall survival (OS), CTCs, CECs and gene expression. Results: 16 pts were enrolled; 13 were eligible with median age 65.5 years, baseline PSA 8.4 ng/mL and median Gleason sum 7. Median of three cycles was administered. Treatment was well tolerated with two grade three toxicities and no grade four toxicities. There were no PSA responses; 11 patients progressed by PSA after three cycles. Median TTP was 1.8 months and median OS has not been reached. Median pre- and on-treatment PSA slopes were 1.1 and 1.8 ng/mL/month. Baseline CTCs were detected in 1/9 patients. CTC increased (0 to 1; 2 pts), remained at 0 (2 pts) or decreased (23 to 0; 1 patient) at progression. Baseline median CEC was 26 (0–61) and at progression, 47 (15–148). Low cell counts precluded gene expression studies. Conclusions: Cilengitide was well tolerated but had no detectable clinical activity. CTCs are of questionable utility in non-metastatic prostate cancer." @default.
• W2034000571 created "2016-06-24" @default.
• W2034000571 creator A5001783218 @default.
• W2034000571 creator A5004935250 @default.
• W2034000571 creator A5010980781 @default.
• W2034000571 creator A5012095437 @default.
• W2034000571 creator A5019390129 @default.
• W2034000571 creator A5039147214 @default.
• W2034000571 creator A5041126882 @default.
• W2034000571 creator A5044876102 @default.
• W2034000571 creator A5045409088 @default.
• W2034000571 creator A5064878844 @default.
• W2034000571 creator A5090879940 @default.
• W2034000571 date "2010-11-04" @default.
• W2034000571 modified "2023-09-23" @default.
• W2034000571 title "Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium" @default.
• W2034000571 cites W1510237891 @default.
• W2034000571 cites W1511542029 @default.
• W2034000571 cites W1546251826 @default.
• W2034000571 cites W1588612022 @default.
• W2034000571 cites W1971040598 @default.
• W2034000571 cites W1974950800 @default.
• W2034000571 cites W1979387004 @default.
• W2034000571 cites W1995470316 @default.
• W2034000571 cites W2000853346 @default.
• W2034000571 cites W2001278383 @default.
• W2034000571 cites W2001753204 @default.
• W2034000571 cites W2007949205 @default.
• W2034000571 cites W2014825000 @default.
• W2034000571 cites W2029718953 @default.
• W2034000571 cites W2029773366 @default.
• W2034000571 cites W2041487686 @default.
• W2034000571 cites W2051147120 @default.
• W2034000571 cites W2053662837 @default.
• W2034000571 cites W2063510784 @default.
• W2034000571 cites W2072700424 @default.
• W2034000571 cites W2073955747 @default.
• W2034000571 cites W2083294486 @default.
• W2034000571 cites W2089786697 @default.
• W2034000571 cites W2099367648 @default.
• W2034000571 cites W2107610316 @default.
• W2034000571 cites W2117098158 @default.
• W2034000571 cites W2120423759 @default.
• W2034000571 cites W2122739907 @default.
• W2034000571 cites W2134771161 @default.
• W2034000571 cites W2139304914 @default.
• W2034000571 cites W2144769242 @default.
• W2034000571 cites W2147761753 @default.
• W2034000571 cites W2148998801 @default.
• W2034000571 cites W2149218924 @default.
• W2034000571 cites W2150402649 @default.
• W2034000571 cites W2150456585 @default.
• W2034000571 cites W2150789897 @default.
• W2034000571 cites W2155679349 @default.
• W2034000571 cites W2156517690 @default.
• W2034000571 cites W2158883289 @default.
• W2034000571 cites W2167331614 @default.
• W2034000571 cites W2171497508 @default.
• W2034000571 cites W4245625325 @default.
• W2034000571 doi "https://doi.org/10.1007/s10637-010-9573-5" @default.
• W2034000571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3175265" @default.
• W2034000571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21049281" @default.
• W2034000571 hasPublicationYear "2010" @default.
• W2034000571 type Work @default.
• W2034000571 sameAs 2034000571 @default.
• W2034000571 citedByCount "69" @default.
• W2034000571 countsByYear W20340005712012 @default.
• W2034000571 countsByYear W20340005712013 @default.
• W2034000571 countsByYear W20340005712014 @default.
• W2034000571 countsByYear W20340005712015 @default.
• W2034000571 countsByYear W20340005712016 @default.
• W2034000571 countsByYear W20340005712017 @default.
• W2034000571 countsByYear W20340005712018 @default.
• W2034000571 countsByYear W20340005712019 @default.
• W2034000571 countsByYear W20340005712020 @default.
• W2034000571 countsByYear W20340005712021 @default.
• W2034000571 countsByYear W20340005712022 @default.
• W2034000571 countsByYear W20340005712023 @default.
• W2034000571 crossrefType "journal-article" @default.
• W2034000571 hasAuthorship W2034000571A5001783218 @default.
• W2034000571 hasAuthorship W2034000571A5004935250 @default.
• W2034000571 hasAuthorship W2034000571A5010980781 @default.
• W2034000571 hasAuthorship W2034000571A5012095437 @default.
• W2034000571 hasAuthorship W2034000571A5019390129 @default.
• W2034000571 hasAuthorship W2034000571A5039147214 @default.
• W2034000571 hasAuthorship W2034000571A5041126882 @default.
• W2034000571 hasAuthorship W2034000571A5044876102 @default.
• W2034000571 hasAuthorship W2034000571A5045409088 @default.
• W2034000571 hasAuthorship W2034000571A5064878844 @default.
• W2034000571 hasAuthorship W2034000571A5090879940 @default.
• W2034000571 hasBestOaLocation W20340005712 @default.
• W2034000571 hasConcept C121608353 @default.
• W2034000571 hasConcept C126322002 @default.
• W2034000571 hasConcept C126894567 @default.
• W2034000571 hasConcept C143998085 @default.
• W2034000571 hasConcept C203092338 @default.
• W2034000571 hasConcept C2776235491 @default.
• W2034000571 hasConcept C2779013556 @default.

• next